Get the Stockscreener App
0.3748
1.76%
-0.0067
After Hours:
.37
-0.0048
-1.28%
Gossamer Bio Inc stock is traded at $0.3748, with a volume of 9.44M.
It is down -1.76% in the last 24 hours and down -6.77% over the past month.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
See More
Previous Close:
$0.3815
Open:
$0.3744
24h Volume:
9.44M
Relative Volume:
0.64
Market Cap:
$87.96M
Revenue:
$44.05M
Net Income/Loss:
$-156.16M
P/E Ratio:
-0.5454
EPS:
-0.6872
Net Cash Flow:
$-158.51M
1W Performance:
-17.08%
1M Performance:
-6.77%
6M Performance:
-86.12%
1Y Performance:
-68.24%
1-Day Range:
$0.3637
$0.4108
1-Week Range:
$0.3213
$0.45
52-Week Range:
$0.3213
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
Name
Gossamer Bio Inc
Sector
Industry
Phone
(858) 684-1300
Address
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.3748 | 89.54M | 44.05M | -156.16M | -158.51M | -0.6872 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-24-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-24-26 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Sep-10-25 | Upgrade | UBS | Neutral → Buy |
| Jul-14-25 | Initiated | Scotiabank | Sector Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-05-24 | Resumed | Wedbush | Outperform |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Mar-07-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-01-23 | Initiated | Guggenheim | Neutral |
| Dec-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-07-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-07-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | JP Morgan | Neutral |
| Sep-19-22 | Initiated | Wedbush | Outperform |
| Apr-18-22 | Initiated | Raymond James | Outperform |
| Apr-06-22 | Initiated | UBS | Buy |
| Jan-10-22 | Upgrade | SMBC Nikko | Neutral → Outperform |
| Nov-09-21 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-21-21 | Resumed | Piper Sandler | Overweight |
| Jun-29-20 | Initiated | H.C. Wainwright | Buy |
| Apr-22-20 | Initiated | Piper Sandler | Overweight |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-30-19 | Initiated | Berenberg | Buy |
| Mar-05-19 | Initiated | Barclays | Overweight |
| Mar-05-19 | Initiated | BofA/Merrill | Buy |
| Mar-05-19 | Initiated | Evercore ISI | Outperform |
| Mar-05-19 | Initiated | SVB Leerink | Outperform |
View All
Gossamer Bio Inc Stock (GOSS) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc.GOSS - PR Newswire
GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial Fails - GlobeNewswire
Options Flow: Is Gossamer Bio Inc a stock for growth or value investorsPortfolio Performance Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLP - PR Newswire
Gossamer Bio (GOSS) continues downtrend despite impressive revenue - MSN
Setup Watch: Should I set a stop loss on Gossamer Bio IncTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Gossamer Bio (GOSS) Continues Downtrend Despite Impressive Revenue - Insider Monkey
683 Capital (GOSS) reports 3.90% position including exercisable warrants - Stock Titan
Gossamer Bio downgraded by Cantor on unclear regulatory path for seralutinib - Seeking Alpha
This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
Gossamer Bio (GOSS) Downgraded to Neutral by Cantor Fitzgerald | - GuruFocus
Cantor Fitzgerald Reiterates "Neutral" Rating for Gossamer Bio (NASDAQ:GOSS) - MarketBeat
Cantor Fitzgerald cuts Gossamer Bio stock rating after trial miss By Investing.com - Investing.com South Africa
Q3 EPS Estimates for Gossamer Bio Boosted by HC Wainwright - MarketBeat
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Gossamer Bio (GOSS) reports topline phase 3 results for seralutinib in pulmonary arterial hypertension - MSN
Gossamer Bio (GOSS) reprices Chief Medical Officer stock options - Stock Titan
Gossamer Bio (GOSS) reprices EVP Caryn Peterson’s stock options to $0.45 - Stock Titan
Gossamer Bio (GOSS) cuts Chief Commercial Officer option strike prices to $0.45 - Stock Titan
Gossamer Bio (GOSS) reprices CEO stock options to $0.45 strike - Stock Titan
Gossamer Bio (GOSS) reprices multiple stock option grants for COO/CFO - Stock Titan
Gossamer Bio (GOSS) cuts EVP Waage option strike to $0.45 in 2.07M-share repricing - Stock Titan
Analysts revise forecasts for Gossamer Bio (GOSS) amid uncertain regulatory environment - MSN
Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment - Yahoo Finance
Biotech company cuts half its staff after disappointing trial sees stock plummet - KRON4
Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace
Big Picture: Does Gossamer Bio Inc stock benefit from AI growth2026 Buyback Activity & Accurate Trade Setup Notifications - baoquankhu1.vn
5 Most Active Penny Stocks to Buy - Insider Monkey
Guggenheim Remains a Hold on Gossamer Bio (GOSS) - The Globe and Mail
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Uncertainty After Phase 3 Setback and Widening Los - AD HOC NEWS
[EFFECT] Gossamer Bio, Inc. SE... | GOSS SEC FilingForm EFFECT - Stock Titan
Calif. biotech company lays off almost half of staff after 78% stock drop - SFGATE
Gossamer Bio plans FDA talks after narrow miss in key pivotal study, stock sinks - MSN
Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart
Gossamer Bio, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Gossamer Bio (NASDAQ:GOSS) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
Gossamer Bio Inc Stock (ISIN: US38198T1034) Faces Investor Lawsuit After Phase 3 Trial Failure and E - AD HOC NEWS
Gossamer Bio (GOSS) reports Q4 loss, beats revenue estimates - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, ... - Bluefield Daily Telegraph
Gossamer Bio earnings missed by $0.02, revenue topped estimates - Investing.com Canada
Gossamer Bio Q4 2025 Earnings: Revenue Beats Forecasts, Loss WidensNews and Statistics - IndexBox
Gossamer Bio (GOSS) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS Exceeds Q4 Revenue Expectations Amid PROSERA Results Analys - GuruFocus
Gossamer Bio Inc. announced that, during the evaluation of the impact of the Prosera trial results on its clinical programs, it has suspended new patient enrollment in the Phase III Seranata study for patients with progressive fibrosing interstitial lung disease (Ph - Bitget
Gossamer Bio: Fourth Quarter Financial Results Overview - Bitget
Gossamer Bio Q4 net loss widens - TradingView
Gossamer Bio (NASDAQ: GOSS) registers up to $200M shelf for equity, debt - Stock Titan
Gossamer Bio: Q4 Earnings Snapshot - marketscreener.com
Gossamer Bio 2025 10-K: Revenue $48.5M, Net loss $170.4M - TradingView
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
Gossamer Bio Inc Stock (GOSS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):